Bank of Ireland said on April 16 it will ask shareholders to approve the cancellation of its secondary listing on the London Stock Exchange at its annual general meeting on May 21, with the delisting expected to take effect on June 29 if approved. The bank cited negligible trading volumes in London and said maintaining the LSE listing is no longer in shareholders’ interests. The move will not affect its primary listing on Euronext Dublin. Concurrently, the lender is seeking permission to launch an “odd‑lot” offer to buy out holders of 30 or fewer shares — a group that represents around 35% of individual shareholders but only about 0.03% of issued share capital — at a 5% premium and with no transaction costs. Bank of Ireland reported a €1.2 billion net profit last year and plans to return the full amount to shareholders via dividends and buybacks. The decision follows a broader trend of companies reassessing dual listings as London has lost other Irish names in recent years, a development seen by some as a setback for the UK market.

April 16, 2026 — Abbott Laboratories trimmed its full-year adjusted profit forecast after completing its acquisition of cancer-test maker Exact Sciences, saying the deal will reduce 2026 earnings by about $0.20 a share. Abbott now expects adjusted EPS of $5.38 to $5.58, down from a prior range of $5.55 to $5.80. The company reported first-quarter revenue of roughly $11.2 billion and adjusted EPS of $1.15, narrowly beating estimates. Diagnostics revenue was about $2.18 billion and medical devices revenue roughly $5.54 billion, while the nutrition business showed continued weakness. Management said the Exact Sciences purchase — valued at roughly $21–23 billion in reported coverage — could add about $3 billion in incremental sales in 2026 but has brought near-term financing and dilution pressures. The guidance revision and acquisition timing prompted an intraday share decline of around 4–6% and sparked investor concern. Abbott also noted limited logistics disruption from the Middle East conflict and said it has boosted local inventories to mitigate supply risks.

Netflix announced on April 16, 2026 that co-founder and chairman Reed Hastings will not stand for re-election when his term expires at the company’s annual meeting in June, and will step away to focus on philanthropy and other pursuits. The governance news accompanied Netflix’s first-quarter results: revenue of $12.25 billion (up ~16% year-on-year), net income of $5.28 billion and earnings per share of $1.23, modestly ahead of forecasts. The company also disclosed it received a $2.8 billion termination fee after walking away from its proposed Warner Bros. acquisition. Shares fell about 8–9% in after-hours trading on the Hastings announcement despite management reiterating full-year guidance. Netflix highlighted growth initiatives — expanding its ad-supported business (targeting roughly $3 billion in ad revenue for 2026), live events, video podcasts, games and product/AI investments — and stressed it will reallocate resources toward content, monetisation and technology under co-CEOs Ted Sarandos and Greg Peters.

Global equity markets rallied on April 15-16, 2026, as hopes for a de-escalation in the U.S.-Iran conflict and a Reuters-reported 10-day Israel-Lebanon ceasefire propelled the S&P 500 and Nasdaq Composite to fresh closing and intraday records. The S&P closed above 7,000 and the Nasdaq notched multi-session winning streaks (11-12 days), while small-cap Russell 2000 also reached record highs. The move was supported by resilient corporate earnings — banks including Morgan Stanley and Bank of America, and PepsiCo surprised on the upside — and stronger-than-expected U.S. jobs data. At the same time oil prices rose (Brent near $99.39, U.S. crude around $94.69) as flows through the Strait of Hormuz remained constrained and global supply buffers tightened. Safe-haven assets and Treasuries eased as risk appetite returned; the dollar retraced some declines. Strategists cautioned that markets were still highly sensitive to news from the Middle East and that further concrete progress on negotiations would be needed to sustain the rally.

Mark Mobius, the intrepid investor widely credited with pioneering emerging-markets investing, died on April 15 at the age of 89, his LinkedIn page said. Known as the “Indiana Jones of emerging markets,” Mobius spent decades travelling to understudied jurisdictions to find undervalued opportunities, helping channel billions of dollars into countries such as India, China, Brazil and other developing economies. He rose to prominence at Templeton Emerging Markets Group, where he served as executive chairman for more than 30 years and later founded Mobius Capital Partners and Mobius Investments. Mobius authored several books, including Passport to Profits and The Little Book of Emerging Markets, and was noted for on-the-ground research and a conviction that volatility signalled opportunity. The announcement did not give a cause of death. In recent years he was based in Dubai and remained an active commentator on markets; he had said as recently as January that changes in Venezuela could reopen investment opportunities. His partners John Ninia and Eric Nguyen will assume leadership responsibilities at Mobius Investments.

Shares of telehealth operator Hims & Hers jumped sharply on April 16-17 after U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said the Food and Drug Administration will convene a Pharmacy Compounding Advisory Committee meeting in July to consider removing a group of peptides from Category 2 restrictions and potentially adding some to the 503A compounding list. The move — described by officials as the start of a multi-stage reassessment that could continue into early 2027 — prompted investor optimism that Hims can scale peptide therapies using its California manufacturing facility acquired in 2025. Analysts and brokerages flagged the change as a positive regulatory pathway but warned revenue impacts will take time. The stock rallied into double-digit gains in one session and posted further intraday strength; market commentary noted a high P/E ratio (around the high 40s to low 50s) and about $3.4 million of recent insider selling. Regulators and clinicians continue to flag limited clinical evidence and safety concerns for many peptide uses — including one, MK-677, that has anti-doping implications — so any policy shift would be gradual and advisory in scope.